Hologic Stock

Hologic FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Hologic (HOLX) as of Sep 12, 2026 is 162.65 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 145.03 % — a change of 12.15% (higher).

FCF Conversion

162.65 %

YoY

12.15%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Hologic is 2026 162.65 % . FCF Conversion Rate (FCF/EBITDA) of Hologic was 2025 145.03 % . It decreases by 12.15% higher compared to the previous year.

The Hologic FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
-563.61 USD
Jan 1, 2019
-1,333.08 USD
Jan 1, 2020
66.37 USD
Jan 1, 2021
115.83 USD
Jan 1, 2022
153.49 USD
Jan 1, 2023
197.59 USD
Jan 1, 2024
145.03 USD
Jan 1, 2025
162.65 USD
The Hologic FCF Conversion history
YEARFCF ConversionYoY
162.65 %+12.15%
145.03 %-26.60%
197.59 %+28.73%
153.49 %+32.52%
115.83 %+74.51%
66.37 %-104.98%
-1,333.08 %+136.53%
-563.61 %+4,188.10%
-13.14 %-106.31%
208.19 %-60.67%
529.41 %-78.61%
2,475.14 %
Access this data via the Eulerpool API

Hologic Stock analysis

What does Hologic do? Hologic Inc. is a company from the United States that has established itself in the medical technology market. The company was founded in 1985 by Jay A. Stein, who set the goal of developing products and services that contribute to improving people's lives. Hologic specializes in artificial intelligence (AI) based diagnostic and therapeutic technology that increases the safety, effectiveness, and accuracy of medical procedures. The company initially focused on products in the field of mammography, but has since expanded to various sectors including imaging, gynecology, skeletal, and surgery. Hologic offers its customers products such as tomosynthesis systems, robot-assisted surgery systems, image analysis software, and a variety of reagents, kits, and tests. The company's business model is focused on innovative technology and science, aiming to optimize medical interventions and thus reduce and improve healthcare costs. Hologic is dedicated to research and development and has already filed dozens of patents. In the field of breast cancer diagnostics, Hologic has developed various mammography systems that have broken the standard of mammography. Through the use of tomosynthesis, a 3D-based diagnostic, it is possible to detect tumors and malignant changes earlier. This procedure has been widely used by many doctors around the world and has proven to be a reliable method for early detection of breast cancer. In gynecology, Hologic specializes in the development of diagnostic tests for infectious agents and hormones. The tests, such as the Aptima HPV test, are fast, sensitive, and reliable. They help to detect infectious agents earlier and initiate appropriate therapy. Hologic Taurus, a robot-assisted surgery system, has been developed to enable minimally invasive interventions that can be used to treat uterine fibroids. This method allows for a drastic reduction in hospital stay duration and recovery time. In the field of skeletal, Hologic offers various systems that are helpful in the diagnosis and treatment of osteoporosis. The widely used DXA system (Dual-Energy X-Ray Absorptiometer) is still one of the most accurate devices for measuring bone density. Additionally, Hologic is an company that not only focuses on medical technology but also pursues the larger goal of improving people's lives. An example of this is their partnership with the organization Pink Ribbon, which serves as a global ambassador for breast cancer early detection. Hologic has developed a special mammography system called Pink Affirm. For every system sold, Hologic donates a certain amount to Pink Ribbon. Overall, Hologic Inc. has become an important player in the field of medical technology and diagnostics. Through its innovative technologies and products, the company contributes to improving the health and lives of people worldwide. Hologic is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hologic stock

FCF Conversion Rate (FCF/EBITDA) of Hologic is 162.65 % in 2026.

FCF Conversion Rate (FCF/EBITDA) of Hologic changed from 145.03 % to 162.65 %, representing a 12.15% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Hologic since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Hologic with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Hologic

All Key Metrics — Hologic